Financial Summary (All financials)
| In millions, except per share items | Jul-31-23 | Jul-31-22 | Jul-31-21 | Jul-31-20 | Jul-31-19 | Jul-31-18 | Jul-31-17 | Jul-31-16 |
| Revenues | 14,368.0 | 12,726.0 | 9,633.0 | 7,679.0 | 6,784.0 | 6,025.0 | 5,196.0 | 4,694.0 |
| Revenue growth | 12.9% | 32.1% | 25.4% | 13.2% | 12.6% | 16.0% | 10.7% | 12.0% |
| Cost of goods sold | 234.0 | 140.0 | 50.0 | 22.0 | 20.0 | 15.0 | 12.0 | 22.0 |
| Gross profit | 14,134.0 | 12,586.0 | 9,583.0 | 7,657.0 | 6,764.0 | 6,010.0 | 5,184.0 | 4,672.0 |
| Gross margin | 98.4% | 98.9% | 99.5% | 99.7% | 99.7% | 99.8% | 99.8% | 99.5% |
| Sales and marketing | 3,762.0 | 3,526.0 | 2,644.0 | 2,048.0 | 1,927.0 | 1,631.0 | 1,415.0 | 1,289.0 |
| Research and development | 2,539.0 | 2,347.0 | 1,678.0 | 1,392.0 | 1,233.0 | 1,186.0 | 998.0 | 881.0 |
| General and administrative | 1,300.0 | 1,460.0 | 982.0 | 679.0 | 597.0 | 664.0 | 553.0 | 518.0 |
| EBITA | 3,787.0 | 3,130.0 | 2,697.0 | 2,205.0 | 1,880.0 | 1,585.0 | 1,440.0 | 1,285.0 |
| EBITA margin | 26.4% | 24.6% | 28.0% | 28.7% | 27.7% | 26.3% | 27.7% | 27.4% |
| Amortization of intangibles | 646.0 | 559.0 | 197.0 | 29.0 | 26.0 | 25.0 | 22.0 | 43.0 |
| EBIT | 3,141.0 | 2,571.0 | 2,500.0 | 2,176.0 | 1,854.0 | 1,560.0 | 1,418.0 | 1,242.0 |
| EBIT margin | 21.9% | 20.2% | 26.0% | 28.3% | 27.3% | 25.9% | 27.3% | 26.5% |
| Pre-tax income | 2,989.0 | 2,542.0 | 2,556.0 | 2,198.0 | 1,881.0 | 1,566.0 | 1,390.0 | 1,203.0 |
| Income taxes | 605.0 | 476.0 | 494.0 | 372.0 | 324.0 | 237.0 | 405.0 | 397.0 |
| Tax rate | 20.2% | 18.7% | 19.3% | 16.9% | 17.2% | 15.1% | 29.1% | 33.0% |
| Net income | 2,384.0 | 2,066.0 | 2,062.0 | 1,826.0 | 1,557.0 | 1,329.0 | 985.0 | 979.0 |
| Net margin | 16.6% | 16.2% | 21.4% | 23.8% | 23.0% | 22.1% | 19.0% | 20.9% |
| |
| Diluted EPS | $8.42 | $7.27 | $7.55 | $6.92 | $5.90 | $5.09 | $3.77 | $3.04 |
| Shares outstanding (diluted) | 283.1 | 284.0 | 273.0 | 264.0 | 264.0 | 261.0 | 261.0 | 265.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|